Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2009, Vol. 14 ›› Issue (6): 655-658.

Previous Articles     Next Articles

Approach on Ch'an su dosage-effect relationship based on the human equivalent dose

MA Hong-yue1,2, DUAN Jing-ao1, ZHOU Jing1, TANG Yu-ping1, PAN Su-hua2, DING An-wei1   

  1. 1Key Laboratory for Modern Research of Chinese Medical Formulae of Jiangsu, 2Department of Clinical Pharmacy of College of Pharmacy Nanjing University of Chinese Medicine, Nanjing 210046, Jiangsu, China
  • Received:2009-02-12 Revised:2009-06-24 Online:2009-06-26 Published:2020-10-27

Abstract: AIM: To approach the clinical dosageeffect relationship of Ch'an su. METHODS: The paper was performed by quoting/Literature data with animal effective doses to converse Ch'an su human equivalent dose (HED) range according to body surface area law. RESULTS: Ch'an su anti-inflammationHED was 9.8-39.2 mg/d, Ch'an su anti-tumor HED was 53.7-104.7 mg/d, the adverse reaction HED was 162-585.4 mg/d. CONCLUSION: Ch'an su anti-inflammation HED was smaller than the recommended dosage (15-30 mg/d), which suggested the clinical dosage is scientific and reasonable.But the anti-tumor HED was high, the upper limit and the HED dosege of secnetio bufonis poisoning were close, which suggested the dosage of Ch'an su for the clinical treatment of tumor should be designed cautiously.

Key words: Ch'an su, human equivalent dose, dose-effect relationship

CLC Number: